<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–43" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–43/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–43/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_43"><akn:num>379j–43</akn:num><akn:heading>Reauthorization; reporting requirements</akn:heading><akn:content><akn:p>§ 379j–43. Reauthorization; reporting requirements(a) Performance report(1) General requirementsNot later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 301(b) 11 See References in Text note below. of the Generic Drug User Fee Amendments of 2022 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals.


(2) Real time reporting(A) In generalNot later than 30 calendar days after the end of each quarter of each fiscal year for which fees are collected under this subpart, the Secretary shall post the data described in subparagraph (B) on the internet website of the Food and Drug Administration, and may remove duplicative data from the annual report under this subsection.


(B) DataThe Secretary shall post the following data in accordance with subparagraph (A):(i) The number and titles of draft and final guidance on topics related to human generic drug activities and whether such guidances were issued as required by statute or pursuant to a commitment under the letters described in section 301(b) 1 of the Generic Drug User Fee Amendments of 2022.

(ii) The number and titles of public meetings held on topics related to human generic drug activities and whether such meetings were required by statute or pursuant to a commitment under the letters described in section 301(b) 1 of the Generic Drug User Fee Amendments of 2022.



(3) Rationale for GDUFA program changesThe Secretary shall include in the annual report under paragraph (1)—(A) data, analysis, and discussion of the changes in the number of individuals hired as agreed upon in the letters described in sec</akn:p></akn:content><akn:subsection eId="subsec_379j_43_a"><akn:num>(a)</akn:num><akn:heading>Performance report</akn:heading><akn:content><akn:p>(a) Performance report</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_43_b"><akn:num>(b)</akn:num><akn:heading>Fiscal report</akn:heading><akn:content><akn:p>(b) Fiscal report Not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_43_c"><akn:num>(c)</akn:num><akn:heading>Corrective action report</akn:heading><akn:content><akn:p>(c) Corrective action report For each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit a corrective action report to the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate. The report shall include the following information, as applicable:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_43_d"><akn:num>(d)</akn:num><akn:heading>Enhanced communication</akn:heading><akn:content><akn:p>(d) Enhanced communication</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_43_e"><akn:num>(e)</akn:num><akn:heading>Public availability</akn:heading><akn:content><akn:p>(e) Public availability The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_43_f"><akn:num>(f)</akn:num><akn:heading>Reauthorization</akn:heading><akn:content><akn:p>(f) Reauthorization</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>